Trial Profile

A Phase 1a Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Dec 2021 Status changed from active, no longer recruiting to completed.
10 Nov 2020 According to an Innovent Biologics media release, Amita Patnaik from South Texas Accelerated Research Therapeutics (START), is the principal investigator of this study.
10 Nov 2020 According to an Innovent Biologics media release, results (as of 18th Jun 2020, n=20) from this study were presented in the form of ePOSTER at the 35th annual meeting of Society for Immunotherapy of Cancer (SITC 2020).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com